What this paper addsWhat is already knownThe evaluation of psychotropic drug effects has been conducted utilising psychometric test batteries to assess changes in daytime cognition and psychomotor functioning and PSG to assess changes in sleep. Actigraphy is widely accepted as a non-invasive tool for assessing sleep-wake patterns in different groups. However, there is limited data to show that actigraphy can reliably measure the daytime and night-time characteristics of a CNS drug.
What this study adds -This study provides further evidence that actigraphy is sensitive not only to the sedating effects of a hypnotic drug but also to the hangover effects of the drug the following morning. It confirms that the actiwatch is able to detect the effects of a hypnotic on actigraphically measured sleep. Further evidence that actigraphy can provide a reliable and sensitive indication of the time course of action of psychoactive drugs.
Lorazepam-induced reduction in activity
3
ABSTRACTAim: To assess whether actigraphy is sensitive to lorazepam-induced changes in cognitive and psychomotor performance by measuring activity levels following placebo and lorazepam (LZP) dosing.Methods: Healthy volunteers were randomised to a double-blind, placebocontrolled, crossover trial. Activity was recorded by actigraphy throughout each test period and pooled into 30 min bins for analysis. Following LZP dosing (2.5 mg at 18.00 h) psychomotor and cognitive tests were conducted at regular intervals.Results: Activity levels were significantly reduced between the psychometric tests (P < 0.02) at 2, 3 and 5 h post dose and during the psychometric tests (P < 0.02) at 2.5 and 4.5 h post dose. Subjects only felt sedated (P < 0.01) at 4.5 h post dose. Activity levels were also significantly reduced (P < 0.05) during sleep (23:00-07:00 h), and the following morning, activity levels remaining suppressed (P < 0.02) at 13.5 and 14 h post dose. Cognitive and psychomotor performance reflected changes in activity levels with significant impairment (P < 0.05) at 2.5, 3.5, 4.5 and 14.5 h post dose.Conclusion: This study showed that actigraphic activity levels were significantly reduced following LZP dosing. These changes were mirrored by impairment of cognitive and psychomotor performance. Actigraphy is therefore sensitive to the sedating effect of LZP and appears able to detect changes in sleep behaviour (hypnotic efficacy) and residual effects the following morning. Actigraphy may thus be a useful tool in assessing the psychopharmacology of CNS medication.
Lorazepam-induced reduction in activity4